French Senate approves latest COVID measures and vaccine pass
Reuters
Published Jan 13, 2022 02:51AM ET
PARIS (Reuters) - The French Senate approved on Thursday the government's latest measures to tackle the COVID-19 virus, including a vaccine pass, which has encountered some opposition among the public after President Emmanuel Macron's harsh criticism of the unvaccinated.
The Senate backed the COVID measures and legislation for a COVID vaccine pass by 249 in favour, versus 63 against. The legislation had already been approved earlier this month by France's lower house of parliament.
Macron and members of his ruling La Republique En Marche party have stepped up their campaign this year against those not vaccinated against COVID, as France battles a fifth wave of the virus.
Macron told Le Parisien paper this month that he wanted to "piss off" unvaccinated people by making their lives so complicated they would end up getting the COVID vaccine.
On Wednesday, France registered 361,719 new COVID cases in the last 24 hours, and a further 246 COVID deaths in hospitals.
French teachers will also walk off the job en masse on Thursday over what they say is a government failure to adopt a coherent policy for schools to manage the COVID pandemic, or properly protect pupils and staff against infection.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.